← Back to patent-cliff list
TAK-733
Tier C — Watch / tradeTAK-733
Takeda Pharmaceutical Company Limited
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：MEK1, MEK2
Indications (approved)：Familial adenomatous polyposis, Solid tumour, Melanoma
Regional status
US
Phase II
2023-07-10
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TAK-733?
Approved indications include: Familial adenomatous polyposis, Solid tumour, Melanoma.
When does the TAK-733 patent expire?
No public expiry year is available for TAK-733 yet; this page updates once verified.
How do I get a quote for TAK-733 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02